PLX:Protalix Biotherapeutics Inc Snapshot | Charting | News | Options
$1.21 NYSE MKT LLC 6:50a ET
March 14 '24 		Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results PR Newswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
     PR Newswire

    Company to host conference call and webcast today at 8:30 a.m. EDT

    Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx(R) plant cell-based protein expression system, today reported financial results for the fiscal year ended December31, 2023, and provided a business update.

    Full Story →

    Headline News
    Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
    6:50a ET February 23 '24 PR Newswire
    More News →
    Day  6.14%Week  0.00%Month  3.20%More Charting →
    May 1 '24. Markets Closed.
    Last $1.21
    Day change   6.14%$0.07
    Open $1.17
    Gap at open $0.03
    Previous close $1.14
    Trading volume 355,268
    10 Day avg vol. 422,838
    Shares out. 73.3Mil
    Market cap. $88.7Mil
    Trading activity Below Avg.
    Previous data from yesterday, April 30 '24.

    Historical Price Performance
    3 month   17.69% 
    6 month   34.59% 
    1 year   54.17% 
    2 year   7.08% 

    Earnings
    Previous 12m $0.07
    Next 12m Estimate $0.21
    P/E ratio 17.5x
    Revenue 65Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.